| GR00053-A | 57135 | NM_020420 | DAZ4 | np | sp | none | | no | | Genome stability | A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability. | Paulsen et al. | 2009 | 19647519 | Cell line | HeLa | gamma-H2AX phosphorylation and DNA content | Fluorescence | siARRAY human genome siRNA library | Genome-wide | siRNA | p-value | Complex criteria | Confidence groupings from 4 to 1 (highest level of confidence in group 4) | GR00054-A | 57135 | NM_020420 | DAZ4 | np | 0.943 | none | | no | | Combinatorial effect with paclitaxel | Synthetic lethal screen identification of chemosensitizer loci in cancer cells. | Whitehurst et al. | 2007 | 17429401 | Cell line | NCI-H1155 | Viability (synthetic lethal) | ATP level | # G-005000-01 | Genome-wide | siRNA | Paclitaxel/control ratio | Complex criteria | Additional information about 87 high-confidence hits | GR00056-A | 57135 | NM_020420 | DAZ4 | np | 0.875 | none | | no | | Melanogenesis | Genome-wide siRNA-based functional genomics of pigmentation identifies novel genes and pathways that impact melanogenesis in human cells. | Ganesan et al. | 2008 | 19057677 | Cell line | MNT-1 | Melanin protein expression and viability | Absorbance and luminescence | rp | Genome-wide | siRNA | Normalized absorbance ratio | > 2 standard deviations below mean | Additional information about a secondary screen (retest to determine false-positive rate) | GR00057-A-1 | 57135 | NM_020364 | DAZ3 | M-021042-00 | 0 | none | | no | | Wnt/beta-catenin pathway regulation (1) | A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. | Tang et al. | 2008 | 18621708 | Cell line | HeLa | Wnt pathway reporter | Luminescence | Human siArray siRNA library | Genome-wide | siRNA | Z-score | > 4 | Screen without Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). | GR00057-A-1 | 57135 | NM_004081 | DAZ | M-011840-00 | 1.12 | none | | no | | Wnt/beta-catenin pathway regulation (1) | A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. | Tang et al. | 2008 | 18621708 | Cell line | HeLa | Wnt pathway reporter | Luminescence | Human siArray siRNA library | Genome-wide | siRNA | Z-score | > 4 | Screen without Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). | GR00057-A-1 | 57135 | NM_020420 | DAZ4 | M-013846-00 | -0.47 | none | | no | | Wnt/beta-catenin pathway regulation (1) | A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. | Tang et al. | 2008 | 18621708 | Cell line | HeLa | Wnt pathway reporter | Luminescence | Human siArray siRNA library | Genome-wide | siRNA | Z-score | > 4 | Screen without Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). | GR00057-A-1 | 57135 | NM_020363 | DAZ2 | M-021073-00 | -0.81 | none | | no | | Wnt/beta-catenin pathway regulation (1) | A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. | Tang et al. | 2008 | 18621708 | Cell line | HeLa | Wnt pathway reporter | Luminescence | Human siArray siRNA library | Genome-wide | siRNA | Z-score | > 4 | Screen without Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). | GR00057-A-2 | 57135 | NM_020363 | DAZ2 | M-021073-00 | sp | none | | no | | Wnt/beta-catenin pathway regulation (2) | A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. | Tang et al. | 2008 | 18621708 | Cell line | HeLa | Wnt pathway reporter | Luminescence | Human siArray siRNA library | Genome-wide | siRNA | Complex, SP | Complex criteria | Screen with Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). | GR00057-A-2 | 57135 | NM_020364 | DAZ3 | M-021042-00 | sp | none | | no | | Wnt/beta-catenin pathway regulation (2) | A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. | Tang et al. | 2008 | 18621708 | Cell line | HeLa | Wnt pathway reporter | Luminescence | Human siArray siRNA library | Genome-wide | siRNA | Complex, SP | Complex criteria | Screen with Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). | GR00057-A-2 | 57135 | NM_004081 | DAZ | M-011840-00 | sp | none | | no | | Wnt/beta-catenin pathway regulation (2) | A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. | Tang et al. | 2008 | 18621708 | Cell line | HeLa | Wnt pathway reporter | Luminescence | Human siArray siRNA library | Genome-wide | siRNA | Complex, SP | Complex criteria | Screen with Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). | GR00057-A-2 | 57135 | NM_020420 | DAZ4 | M-013846-00 | sp | none | | no | | Wnt/beta-catenin pathway regulation (2) | A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. | Tang et al. | 2008 | 18621708 | Cell line | HeLa | Wnt pathway reporter | Luminescence | Human siArray siRNA library | Genome-wide | siRNA | Complex, SP | Complex criteria | Screen with Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). | GR00180-A-1 | 57135 | 57135 | DAZ4 | PL-50062 | 0.908 | none | | no | | Hepatitis C virus replication (1) | A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. | Tai et al. | 2009 | 19286138 | Cell line | Huh7/Rep-Feo | HCV replicon RNA copy number | Luminescence | siARRAY Human Genome siRNA Library | Genome-wide | siRNA | q-value | Complex criteria | | GR00184-A-1 | 57135 | NM_020363 | DAZ2 | M-021073-00 | -0.33457236205302 | none | | no | | Self-renewal and pluripotency in human embryonic stem cells (1) | A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. | Chia et al. | 2010 | 20953172 | Cell line | hESC H1 | POU5F1 protein expression | Fluorescence | SMARTpool siRNA library | Genome-wide | siRNA | Z-score | < -2 | | GR00184-A-1 | 57135 | NM_004081 | DAZ1 | M-011840-00 | -0.54169396167178 | none | | no | | Self-renewal and pluripotency in human embryonic stem cells (1) | A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. | Chia et al. | 2010 | 20953172 | Cell line | hESC H1 | POU5F1 protein expression | Fluorescence | SMARTpool siRNA library | Genome-wide | siRNA | Z-score | < -2 | | GR00184-A-1 | 57135 | NM_020420 | DAZ4 | M-013846-00 | -0.135332794802206 | none | | no | | Self-renewal and pluripotency in human embryonic stem cells (1) | A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. | Chia et al. | 2010 | 20953172 | Cell line | hESC H1 | POU5F1 protein expression | Fluorescence | SMARTpool siRNA library | Genome-wide | siRNA | Z-score | < -2 | | GR00184-A-1 | 57135 | NM_020364 | DAZ3 | M-021042-00 | -0.111822983213091 | none | | no | | Self-renewal and pluripotency in human embryonic stem cells (1) | A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. | Chia et al. | 2010 | 20953172 | Cell line | hESC H1 | POU5F1 protein expression | Fluorescence | SMARTpool siRNA library | Genome-wide | siRNA | Z-score | < -2 | | GR00197-A-1 | 57135 | 57135 | DAZ4 | M-013846-00 | -1.279761457 | none | | no | | Human papillomavirus oncogene expression regulation (1) | Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 as E2-dependent regulators of human papillomavirus oncogene expression. | Smith et al. | 2010 | 20133580 | Cell line | C33A/BE2/18LCR c4 | HPV18 LCR reporter activity | Luminescence | Human siGENOME SMARTpool library | Genome-wide | siRNA | Z-score | > | Author-submitted data. Phenotype strength according to Z-scores: weak: 2 - 3; moderate: 3 - 5; strong: > 5 | GR00197-A-1 | 57135 | 57054 | DAZ3 | M-021042-00 | 0.296859823 | none | | no | | Human papillomavirus oncogene expression regulation (1) | Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 as E2-dependent regulators of human papillomavirus oncogene expression. | Smith et al. | 2010 | 20133580 | Cell line | C33A/BE2/18LCR c4 | HPV18 LCR reporter activity | Luminescence | Human siGENOME SMARTpool library | Genome-wide | siRNA | Z-score | > | Author-submitted data. Phenotype strength according to Z-scores: weak: 2 - 3; moderate: 3 - 5; strong: > 5 | GR00197-A-1 | 57135 | 1617 | DAZ1 | M-011840-00 | 1.163954311 | none | | no | | Human papillomavirus oncogene expression regulation (1) | Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 as E2-dependent regulators of human papillomavirus oncogene expression. | Smith et al. | 2010 | 20133580 | Cell line | C33A/BE2/18LCR c4 | HPV18 LCR reporter activity | Luminescence | Human siGENOME SMARTpool library | Genome-wide | siRNA | Z-score | > | Author-submitted data. Phenotype strength according to Z-scores: weak: 2 - 3; moderate: 3 - 5; strong: > 5 | GR00197-A-1 | 57135 | 57055 | DAZ2 | M-021073-00 | 0.057379797 | none | | no | | Human papillomavirus oncogene expression regulation (1) | Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 as E2-dependent regulators of human papillomavirus oncogene expression. | Smith et al. | 2010 | 20133580 | Cell line | C33A/BE2/18LCR c4 | HPV18 LCR reporter activity | Luminescence | Human siGENOME SMARTpool library | Genome-wide | siRNA | Z-score | > | Author-submitted data. Phenotype strength according to Z-scores: weak: 2 - 3; moderate: 3 - 5; strong: > 5 | GR00236-A-1 | 57135 | 1617 | DAZ1 | M-011840-00 | 1.47795716996335 | none | | no | | Homologous recombination DNA double-strand break repair (HR-DSBR) (1) | A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. | Adamson et al. | 2012 | 22344029 | Cell line | DR-U2OS | (HR-DSBR) DR-GFP reporter and DNA content | Fluorescence | Human siGENOME siRNA (G-005000-05) | Genome-wide | siRNA | Relative HR ratio | < ~0.4 OR > 1.88 | Cutoff values correspond 2 standard deviations from the screen-wide mean | GR00236-A-1 | 57135 | 57054 | DAZ3 | M-021042-00 | 1.85930958023305 | none | | no | | Homologous recombination DNA double-strand break repair (HR-DSBR) (1) | A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. | Adamson et al. | 2012 | 22344029 | Cell line | DR-U2OS | (HR-DSBR) DR-GFP reporter and DNA content | Fluorescence | Human siGENOME siRNA (G-005000-05) | Genome-wide | siRNA | Relative HR ratio | < ~0.4 OR > 1.88 | Cutoff values correspond 2 standard deviations from the screen-wide mean | GR00236-A-1 | 57135 | 57135 | DAZ4 | M-013846-00 | 2.25613765392291 | Increased homologous recombination repair frequency | | yes | | Homologous recombination DNA double-strand break repair (HR-DSBR) (1) | A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. | Adamson et al. | 2012 | 22344029 | Cell line | DR-U2OS | (HR-DSBR) DR-GFP reporter and DNA content | Fluorescence | Human siGENOME siRNA (G-005000-05) | Genome-wide | siRNA | Relative HR ratio | < ~0.4 OR > 1.88 | Cutoff values correspond 2 standard deviations from the screen-wide mean | GR00236-A-1 | 57135 | 57055 | DAZ2 | M-021073-00 | 1.72797693777994 | none | | no | | Homologous recombination DNA double-strand break repair (HR-DSBR) (1) | A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. | Adamson et al. | 2012 | 22344029 | Cell line | DR-U2OS | (HR-DSBR) DR-GFP reporter and DNA content | Fluorescence | Human siGENOME siRNA (G-005000-05) | Genome-wide | siRNA | Relative HR ratio | < ~0.4 OR > 1.88 | Cutoff values correspond 2 standard deviations from the screen-wide mean | | 57135 | 57135 | DAZ4 | D-013846-01 | 2.84 | Increased homologous recombination repair frequency | | no | strong cutoff | | | | | | | | | | | | | | | | | 57135 | 57135 | DAZ4 | D-013846-04 | 2.45 | Increased homologous recombination repair frequency | | no | strong cutoff | | | | | | | | | | | | | | | | GR00240-S-1 | 57135 | NM_020364 | DAZ3 | M-021042-00 | 1.77 | none | | yes | | TRAIL-induced apoptosis (1) | A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. | Kranz and Boutros | 2014 | 24442637 | Cell line | U251MG | Viability | Luminescence | SMART-pool siRNA | Genome-wide | siRNA | Z-score | > 4 | Author-submitted data | GR00240-S-1 | 57135 | NM_020363 | DAZ2 | M-021073-00 | -0.21 | none | | yes | | TRAIL-induced apoptosis (1) | A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. | Kranz and Boutros | 2014 | 24442637 | Cell line | U251MG | Viability | Luminescence | SMART-pool siRNA | Genome-wide | siRNA | Z-score | > 4 | Author-submitted data | GR00240-S-1 | 57135 | NM_020420 | DAZ4 | M-013846-00 | 1.18 | none | | yes | | TRAIL-induced apoptosis (1) | A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. | Kranz and Boutros | 2014 | 24442637 | Cell line | U251MG | Viability | Luminescence | SMART-pool siRNA | Genome-wide | siRNA | Z-score | > 4 | Author-submitted data | GR00240-S-1 | 57135 | NM_004081 | DAZ | M-011840-00 | 2.27 | none | | yes | | TRAIL-induced apoptosis (1) | A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. | Kranz and Boutros | 2014 | 24442637 | Cell line | U251MG | Viability | Luminescence | SMART-pool siRNA | Genome-wide | siRNA | Z-score | > 4 | Author-submitted data | GR00240-S-2 | 57135 | NM_020363 | DAZ2 | M-021073-00 | 0.02 | none | | no | Z-score -0.214 | TRAIL-induced apoptosis (2) | A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. | Kranz and Boutros | 2014 | 24442637 | Cell line | U251MG | Viability (synthetic lethal) | Luminescence | SMART-pool siRNA | Genome-wide | siRNA | Differential score | > 3.6 AND viability Z-score < 4 | Author-submitted data. Z-scores from viability screen (1) are considered in score interpretation for this screen. | GR00240-S-2 | 57135 | NM_020420 | DAZ4 | M-013846-00 | -0.8 | none | | no | Z-score 0.463 | TRAIL-induced apoptosis (2) | A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. | Kranz and Boutros | 2014 | 24442637 | Cell line | U251MG | Viability (synthetic lethal) | Luminescence | SMART-pool siRNA | Genome-wide | siRNA | Differential score | > 3.6 AND viability Z-score < 4 | Author-submitted data. Z-scores from viability screen (1) are considered in score interpretation for this screen. | GR00240-S-2 | 57135 | NM_004081 | DAZ | M-011840-00 | -1.04 | none | | no | Z-score 1.4925 | TRAIL-induced apoptosis (2) | A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. | Kranz and Boutros | 2014 | 24442637 | Cell line | U251MG | Viability (synthetic lethal) | Luminescence | SMART-pool siRNA | Genome-wide | siRNA | Differential score | > 3.6 AND viability Z-score < 4 | Author-submitted data. Z-scores from viability screen (1) are considered in score interpretation for this screen. | GR00240-S-2 | 57135 | NM_020364 | DAZ3 | M-021042-00 | 0.53 | none | | no | Z-score 2.506 | TRAIL-induced apoptosis (2) | A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. | Kranz and Boutros | 2014 | 24442637 | Cell line | U251MG | Viability (synthetic lethal) | Luminescence | SMART-pool siRNA | Genome-wide | siRNA | Differential score | > 3.6 AND viability Z-score < 4 | Author-submitted data. Z-scores from viability screen (1) are considered in score interpretation for this screen. | GR00242-A-1 | 57135 | NM_020420 | DAZ4 | np | sp | none | | no | | Selective autophagy regulation (1) | Image-based genome-wide siRNA screen identifies selective autophagy factors. | Orvedahl et al. | 2011 | 22020285 | Cell line | HeLa/GFP-LC3 | Sindbis virus (SIN) capsid SIN-mCherry.capsid and autophagosome GFP–LC3 protein expression | Fluorescence | siGenome | Genome-wide | siRNA | Z-score | Complex criteria | | GR00247-A-1 | 57135 | | DAZ4 | np | sp | none | | | rank: 662 | Regulation of FOXO1 nuclear localization (1) | Whole genome siRNA cell-based screen links mitochondria to Akt signaling network through uncoupling of electron transport chain. | Senapedis et al. | 2011 | 21460183 | Cell line | U2OS | EGFP-FOXO1a protein expression and DNA content | Fluorescence | Human Genome library | Genome-wide | siRNA | Complex, sp | Complex criteria | | GR00249-S | 57135 | 57135 | DAZ4 | J-013846-17 | 0.01083 | none | | no | number of cells compared to control (%): 87.22 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 57135 | 57135 | DAZ4 | M-013846-01 | -2.02548 | Decreased vaccinia virus (VACV) infection | | no | number of cells compared to control (%): 66.29 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00250-A-1 | 57135 | 57054 | DAZ3 | M-021042-00 | sp | Synthetic lethal with MLN4924 (a NAE inhibitor) | | | duplicate screen, sextuplicate screen | Combinatorial effect with MLN4924, a NAE inhibitor (1) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Genome-wide | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-1 | 57135 | 57055 | DAZ2 | M-021073-00 | sp | Synthetic lethal with MLN4924 (a NAE inhibitor) | | | duplicate screen, sextuplicate screen | Combinatorial effect with MLN4924, a NAE inhibitor (1) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Genome-wide | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-1 | 57135 | 57135 | DAZ4 | M-013846-00 | sp | Synthetic lethal with MLN4924 (a NAE inhibitor) | | | duplicate screen, sextuplicate screen | Combinatorial effect with MLN4924, a NAE inhibitor (1) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Genome-wide | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 57135 | 57054 | DAZ3 | D-021042-01 | sp | Synthetic lethal with MLN4924 (a NAE inhibitor) | | | duplicate screen, sextuplicate screen; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 57135 | 57054 | DAZ3 | D-021042-04 | sp | Synthetic lethal with MLN4924 (a NAE inhibitor) | | | duplicate screen, sextuplicate screen; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 57135 | 57135 | DAZ4 | D-013846-01 | sp | Synthetic lethal with MLN4924 (a NAE inhibitor) | | | duplicate screen, sextuplicate screen; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 57135 | 57135 | DAZ4 | D-013846-04 | sp | Synthetic lethal with MLN4924 (a NAE inhibitor) | | | duplicate screen, sextuplicate screen; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-3 | 57135 | 57054 | DAZ3 | D-021042-01 | sp | Increased viability with MLN4924 (a NAE inhibitor) | | | 116 nM MLN4924, 91 nM MLN4924; set: Top240; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (3) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | HCT116 | Viability (synthetic lethal) | Luminescence | np | Selected and random genes | siRNA | Complex, sp | Complex criteria | | GR00250-A-3 | 57135 | 57054 | DAZ3 | D-021042-04 | sp | Synthetic lethal with MLN4924 (a NAE inhibitor) | | | 116 nM MLN4924, 91 nM MLN4924; set: Top240; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (3) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | HCT116 | Viability (synthetic lethal) | Luminescence | np | Selected and random genes | siRNA | Complex, sp | Complex criteria | | GR00250-A-3 | 57135 | 57135 | DAZ4 | D-013846-01 | sp | Increased viability with MLN4924 (a NAE inhibitor) | | | 116 nM MLN4924, 91 nM MLN4924; set: Top240; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (3) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | HCT116 | Viability (synthetic lethal) | Luminescence | np | Selected and random genes | siRNA | Complex, sp | Complex criteria | | GR00250-A-3 | 57135 | 57135 | DAZ4 | D-013846-04 | sp | Synthetic lethal with MLN4924 (a NAE inhibitor) | | | 116 nM MLN4924, 91 nM MLN4924; set: Top240; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (3) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | HCT116 | Viability (synthetic lethal) | Luminescence | np | Selected and random genes | siRNA | Complex, sp | Complex criteria | | GR00253-A | 57135 | NM_020420 | DAZ4 | np | -0.928 | none | | | | hepcidin regulation | Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras/RAF and nutrient-dependent mTOR signaling. | Mleczko-Sanecka et al. | 2014 | 24385536 | Cell line | Huh7 | hepcidin::fluc mRNA expression | Luminescence | siGenome siARRAY SMARTpool | Genome-wide | siRNA | Z-score | > | Cutoff < | GR00254-A | 57135 | | DAZ4 | np | np | none | | | | SMN2 splicing regulation | Nuclear matrix factor hnRNP U/SAF-A exerts a global control of alternative splicing by regulating U2 snRNP maturation. | Xiao et al. | 2012 | 22325991 | Cell line | HeLa | SMN2-based splicing reporter expression | Real-time PCR | rp | RNA-binding proteins | esiRNA | SMN2 FL/deltaexon 7 ratio | np | | GR00255-A-1 | 57135 | 57055 | DAZ2 | TRCN0000083759, TRCN0000083760, TRCN0000083762 | 1.026120844 | none | | | | Negative genetic interactions (1) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.0 | HCT116 BLM-/- and HCT116 BLM+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-1 | 57135 | 57054 | DAZ3 | TRCN0000152171, TRCN0000152311, TRCN0000153130, TRCN0000154176, TRCN0000157295 | 0.334064628 | none | | | | Negative genetic interactions (1) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.0 | HCT116 BLM-/- and HCT116 BLM+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-1 | 57135 | 1617 | DAZ1 | TRCN0000119017, TRCN0000119020, TRCN0000119021 | -0.20733396 | none | | | | Negative genetic interactions (1) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.0 | HCT116 BLM-/- and HCT116 BLM+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-2 | 57135 | 57054 | DAZ3 | TRCN0000152171, TRCN0000152311, TRCN0000153130, TRCN0000154176, TRCN0000157295 | 0.700421676 | none | | | | Negative genetic interactions (2) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.0 | HCT116 MUS81-/- and HCT116 MUS81+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-2 | 57135 | 1617 | DAZ1 | TRCN0000119017, TRCN0000119020, TRCN0000119021 | -0.003683462 | none | | | | Negative genetic interactions (2) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.0 | HCT116 MUS81-/- and HCT116 MUS81+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-2 | 57135 | 57055 | DAZ2 | TRCN0000083759, TRCN0000083760, TRCN0000083762 | 0.689400745 | none | | | | Negative genetic interactions (2) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.0 | HCT116 MUS81-/- and HCT116 MUS81+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-3 | 57135 | 57055 | DAZ2 | TRCN0000083759, TRCN0000083760, TRCN0000083762 | 1.490077406 | none | | | | Negative genetic interactions (3) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.2 | HCT116 PTEN-/- and HCT116 PTEN+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-3 | 57135 | 57054 | DAZ3 | TRCN0000152171, TRCN0000152311, TRCN0000153130, TRCN0000154176, TRCN0000157295 | 0.730108389 | none | | | | Negative genetic interactions (3) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.2 | HCT116 PTEN-/- and HCT116 PTEN+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-3 | 57135 | 1617 | DAZ1 | TRCN0000119017, TRCN0000119020, TRCN0000119021 | -0.637816862 | none | | | | Negative genetic interactions (3) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.2 | HCT116 PTEN-/- and HCT116 PTEN+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-4 | 57135 | 57054 | DAZ3 | TRCN0000152171, TRCN0000152311, TRCN0000153130, TRCN0000154176, TRCN0000157295 | 0.3479599 | none | | | | Negative genetic interactions (4) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.2 | HCT116 PTTG1-/- and HCT116 PTTG1+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-4 | 57135 | 1617 | DAZ1 | TRCN0000119017, TRCN0000119020, TRCN0000119021 | -0.757843544 | none | | | | Negative genetic interactions (4) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.2 | HCT116 PTTG1-/- and HCT116 PTTG1+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-4 | 57135 | 57055 | DAZ2 | TRCN0000083759, TRCN0000083760, TRCN0000083762 | 0.306264474 | none | | | | Negative genetic interactions (4) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.2 | HCT116 PTTG1-/- and HCT116 PTTG1+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-5 | 57135 | 1617 | DAZ1 | TRCN0000119017, TRCN0000119020, TRCN0000119021 | 0.253300974 | none | | | | Negative genetic interactions (5) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -0.8 | HCT116 KRASG13D/- and HCT116 KRAS+/- cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-5 | 57135 | 57054 | DAZ3 | TRCN0000152171, TRCN0000152311, TRCN0000153130, TRCN0000154176, TRCN0000157295 | -0.639705926 | none | | | | Negative genetic interactions (5) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -0.8 | HCT116 KRASG13D/- and HCT116 KRAS+/- cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-5 | 57135 | 57055 | DAZ2 | TRCN0000083759, TRCN0000083760, TRCN0000083762 | -0.913041222 | Negative genetic interaction between KRASG13D/+ and KRAS+/- | | | | Negative genetic interactions (5) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -0.8 | HCT116 KRASG13D/- and HCT116 KRAS+/- cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00293-A | 57135 | | DAZ4 | np | -1.978 | none | | | | Combinatorial effect with paclitaxel | Mechanisms Promoting Escape from Mitotic Stress−Induced Tumor Cell Death | Sinnott et al. | 2014 | 24860162 | Cell line | HCC366 | Viability | Luminescence | Thermo-Fisher | Genome-wide | siRNA | Z-score | < -2.5 | Final hits according to the author are indicated in the comment. | GR00300-A | 57135 | | DAZ1 | TRCN0000119021, TRCN0000119017 | 0 | none | | | | Combinatorial effect with RAF inhibitor PLX4720 | A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. | Whittaker et al. | 2013 | 23288408 | Cell line | A375 | shRNA abundance | Sequencing | TRC | Genome-wide | shRNA | Number of shRNAs ranked Top1000 | > 2 | The A375 cell line used here harbours the BRAF V600E mutation and is therefore sensitive to RAF inhibitors. | GR00300-A | 57135 | | DAZ3 | TRCN0000153130, TRCN0000157295, TRCN0000152311, TRCN0000154176, TRCN0000152171 | 0 | none | | | | Combinatorial effect with RAF inhibitor PLX4720 | A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. | Whittaker et al. | 2013 | 23288408 | Cell line | A375 | shRNA abundance | Sequencing | TRC | Genome-wide | shRNA | Number of shRNAs ranked Top1000 | > 2 | The A375 cell line used here harbours the BRAF V600E mutation and is therefore sensitive to RAF inhibitors. | GR00300-A | 57135 | | DAZ4 | TRCN0000157422, TRCN0000156515, TRCN0000151232, TRCN0000151309, TRCN0000150581, TRCN0000158257, TRCN0000157556, TRCN0000150791, TRCN0000150746 | 0 | none | | | | Combinatorial effect with RAF inhibitor PLX4720 | A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. | Whittaker et al. | 2013 | 23288408 | Cell line | A375 | shRNA abundance | Sequencing | TRC | Genome-wide | shRNA | Number of shRNAs ranked Top1000 | > 2 | The A375 cell line used here harbours the BRAF V600E mutation and is therefore sensitive to RAF inhibitors. | GR00303-A | 57135 | NM_020420 | DAZ4 | np | -0.02 | none | | | | Clear cell renal cell carcinoma (ccRCC) survival regulation | Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target | Gerlinger et al. | 2012 | 22362593 | Cell line | VHL-deficient RCC4 | Proliferation and Viability | Fluorescence | np | Genome-wide | siRNA | Z-score | < | In the phenotype data duplicates were in the original document, which have been removed. | | 57135 | 57135 | DAZ4 | np | 69.5 | Decreased NF-kappaB reporter expression | | | 75,1% viability | | | | | | | | | | | | | | | | GR00313-A | 57135 | NM_001005375 | DAZ4 | np | -0.69 | none | | | | TNF-alpha pathway regulation | A Genome-Wide RNA Interference Screen Identifies Caspase 4 as a Factor Required for Tumor Necrosis Factor Alpha Signaling. | Nickles et al. | 2012 | 22733992 | Cell line | HEK293T | NFkappaB pathway reporter | Luminescence | Qiagen | Genome-wide | siRNA | Z-score | < | Additional filters were a reduction in firefly luciferase levels by at least 50% compared to the mean of the experiment and a concomitant reduction of renilla luciferase expression of not more than 30%. | | 57135 | 57135 | DAZ4 | | -0.04999999999999999 | none | | | | | | | | | | | | | | | | | | | GR00378-A | 57135 | | DAZ4 | | -0.606716762 | none | | | | Poliovirus vaccine production | Engineering Enhanced Vaccine Cell Lines To Eradicate Vaccine-Preventable Diseases: the Polio End Game | van der Sanden et al. | 2015 | 26581994 | Cell line | HEp-2C | Infection with Attenuated Poliovirus | ELISA | Dharmacon | Genome-wide | siRNA | Z-score | > | For infection, a single lot of the attenuated Sabin type 2 poliovirus was used for the screen. Gene IDs were not provided, only the gene name/symbol | | 57135 | NM_020420 | DAZ4 | | 22.854 | Decreased viability | | | | | | | | | | | | | | | | | | | GR00386-A-1 | 57135 | 57135 | DAZ4 | | 76.3787415582845 | none | | | | NOD2 stimulation by MDP | A genome-wide small interfering RNA (siRNA) screen reveals nuclear factor-κB (NF-κB)-independent regulators of NOD2-induced interleukin-8 (IL-8) secretion. | Warner et al. | 2014 | 25170077 | Cell line | HEK293 stably expressing NOD2 | Viability | Luminescence | Dharmacon | Genome-wide | siRNA | Percentage growth | Decreased: <70, increased: >120 | Reagent IDs not provided | GR00386-A-2 | 57135 | 57135 | DAZ4 | | 34.4 | none | | | | MDP-induced IL-8 secretion | A genome-wide small interfering RNA (siRNA) screen reveals nuclear factor-κB (NF-κB)-independent regulators of NOD2-induced interleukin-8 (IL-8) secretion. | Warner et al. | 2014 | 25170077 | Cell line | HEK293 stably expressing NOD2 | IL-8 secretion | ELISA | Dharmacon | Genome-wide | siRNA | Percent inhibition of IL-8 secretion | Increased: <-300, Decreased: >60 | Concentration of IL-8 was measured from cell supernatants by sandwich ELISA. IL-8 values (pg/ml) were normalized to IL-8 secreted in cells treated with RIPK2-specific siRNA (100% inhibition) and non-targeting siRNA (0% inhibition). Secondary validating screen assessed 554 genes whose silencing affected MDP-induced IL-8 secretion in the primary screen. Final validated IL-8 regulators (positive or negative) are listed in the comments column. Reagent IDs not provided |